Sostos LLC
Sostos has developed a unique software platform technology that utilizes AI and big data to identify optimal treatment solutions for cancer patients.
- Stage Prototype Ready
- Industry Software
- Location Morgantown, WV, USA
- Currency USD
- Founded October 2020
- Employees 11
- Incorporation Type LLC
- Website sostosllc.com
Company Summary
Sostos has developed unique AI software that utilizes big data to identify optimal treatment solutions for each patient. Our CATOS products predict the best-personalized cancer care from cancer screening, biopsies, diagnosis, prognosis, and treatment selection, to new drug options for patients. Our lead product, CATOS-LU (FDA-classified novel technology) has been validated in > 1,641 lung cancer patients including a phase III clinical trial.
Team
-
Founder and Scientific AdvisorDr. Guo obtained more than $45.5 M funding from NIH/NSF/CDC as Principal Investigator/Project Director to develop technology and infrastructure for precision medicine. Dr. Guo has 13 patents (3 awarded and 10 pending). Dr. Guo's AI technology is proven effective with 61 peer reviewed journal publications of more than 3,800 citations.
-
CEODr. Flynn is an experienced cancer researcher with the successful exit of two biotech startups. Dr. Flynn was the scientific creator of Protea Biosciences, a biotechnology company that lasted 17 years and employed 50 employees before its IPO. Dr. Flynn also served on the board of BioArkive and assisted with the M&A of the company to Immuneering, Inc (12/20/21).
-
Chief Technology OfficerDr. Qing Ye is PI of a NSF SBIR awarded to Sostos. Dr. Ye is experienced in AI software development, open source software, high-performance computer coding, and health analytics.
Advisors
-
Stephen Carrithers, Ph.D., President, Director of R&D, LAGRANGE SCIENTIFIC, LLCUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.